Terms: = Liver cancer AND UBR5, EDD, 51366, ENSG00000104517, EDD1, KIAA0896, HYD, MGC57263, DD5, O95071, FLJ11310
11 results:
1. ubr5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability.
Tsai JM; Aguirre JD; Li YD; Brown J; Focht V; Kater L; Kempf G; Sandoval B; Schmitt S; Rutter JC; Galli P; Sandate CR; Cutler JA; Zou C; Donovan KA; Lumpkin RJ; Cavadini S; Park PMC; Sievers Q; Hatton C; Ener E; Regalado BD; Sperling MT; Słabicki M; Kim J; Zon R; Zhang Z; Miller PG; Belizaire R; Sperling AS; Fischer ES; Irizarry R; Armstrong SA; Thomä NH; Ebert BL
Mol Cell; 2023 Aug; 83(15):2753-2767.e10. PubMed ID: 37478846
[TBL] [Abstract] [Full Text] [Related]
2. pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma.
Pan X; Huang J; Liu S; Shao Y; Xi J; He R; Shi T; Zhuang R; Yu W
Drug Dev Ind Pharm; 2023 Aug; 49(8):485-496. PubMed ID: 37470495
[TBL] [Abstract] [Full Text] [Related]
3. The effects of folic acid supplementation on endothelial function in adults: a systematic review and dose-response meta-analysis of randomized controlled trials.
Zamani M; Rezaiian F; Saadati S; Naseri K; Ashtary-Larky D; Yousefi M; Golalipour E; Clark CCT; Rastgoo S; Asbaghi O
Nutr J; 2023 Feb; 22(1):12. PubMed ID: 36829207
[TBL] [Abstract] [Full Text] [Related]
4. Clinicopathological Features and Prognostic Evaluation of ubr5 in liver cancer Patients.
Huo Q; Hu J; Hou B; Zhao M; Han X; Du Y; Li Y
Pathol Oncol Res; 2022; 28():1610396. PubMed ID: 36388433
[No Abstract] [Full Text] [Related]
5. Targeting ubr5 in hepatocellular carcinoma cells and precise treatment via echinacoside nanodelivery.
Wang M; Ma X; Wang G; Song Y; Zhang M; Mai Z; Zhou B; Ye Y; Xia W
Cell Mol Biol Lett; 2022 Oct; 27(1):92. PubMed ID: 36224534
[TBL] [Abstract] [Full Text] [Related]
6. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
Lages EB; Fernandes RS; Andrade MMS; Paiyabhroma N; de Oliveira RB; Fernandes C; Cassali GD; Sicard P; Richard S; Branco de Barros AL; Ferreira LAM
Biomed Pharmacother; 2021 Dec; 144():112373. PubMed ID: 34794238
[TBL] [Abstract] [Full Text] [Related]
7. C2orf40 inhibits hepatocellular carcinoma through interaction with ubr5.
Wu Y; Xiang Q; Lv X; Xiang X; Feng Z; Tian S; Tang J; Xiang T; Gong J
J Gastroenterol Hepatol; 2021 Sep; 36(9):2581-2591. PubMed ID: 33576531
[TBL] [Abstract] [Full Text] [Related]
8. Hepatitis B Core Protein Is Post-Translationally Modified through K29-Linked Ubiquitination.
Langerová H; Lubyová B; Zábranský A; Hubálek M; Glendová K; Aillot L; Hodek J; Strunin D; Janovec V; Hirsch I; Weber J
Cells; 2020 Nov; 9(12):. PubMed ID: 33256078
[TBL] [Abstract] [Full Text] [Related]
9. Alleviation of fatty liver in a rat model by enhancing N
Takeuchi K; Yokouchi C; Goto H; Umehara K; Yamada H; Ishii Y
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):203-210. PubMed ID: 30446221
[TBL] [Abstract] [Full Text] [Related]
10. [SCLEROUSIS CHOLANGITIS AT THE AUTOIMMUNE PANCREATITIS PATIENT].
Gavrilina NS; Sedova GA; Kosyura SD; Fedorov IG; Ilchenko LY; Storozhakov G
Eksp Klin Gastroenterol; 2015; (7):78-84. PubMed ID: 26817126
[TBL] [Abstract] [Full Text] [Related]
11. Synthesis of doxorubicin α-linolenic acid conjugate and evaluation of its antitumor activity.
Liang CH; Ye WL; Zhu CL; Na R; Cheng Y; Cui H; Liu DZ; Yang ZF; Zhou SY
Mol Pharm; 2014 May; 11(5):1378-90. PubMed ID: 24720787
[TBL] [Abstract] [Full Text] [Related]
